Target other gene point mutations: HER2 and rare EGFR mutations Source: ERS Research Seminar Year: 2015
EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype Source: Eur Respir J 2014; 43: 872-883 Year: 2014
Asbestos-related lung cancers are rarely associated with ALK , ROS1 and RET rearrangements Source: Eur Respir J, 51 (3) 1702605; 10.1183/13993003.02605-2017 Year: 2018
Immunohistochemistry versus DNA testing for detection of EGFR mutations and ALK rearrangements in lung adenocarcinoma patients Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014
Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib? Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
MDM2 gene amplification and mdm2 protein expression in NSCLC cells Source: Eur Respir J 2005; 26: Suppl. 49, 91s Year: 2005
Molecular profiling of Sq-NSCLC with enhanced FGFR1-4 and MET gene expression – NGS pilot study. Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020
Evaluation of four different molecular methods for EGFR mutation analysis in exon 18, 19 and 21 Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011
Mapping of KRAS mutations during chemical carcinogenesis Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases Year: 2020
Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014
Diagnostic utility of PNA-LNA PCR clamp method for detection of EGFR exon 19 deletions and exon 21 codon L858 mutations in NSCLC samples with low tumor cells content Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012
European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology Source: International Congress 2015 – Quality management in lung cancer Year: 2015
Very early detection of small clones harbouring EGFR mutations in NSCLC by 2nd generation sequencing Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011
(Array)CGH analysis of chromosomal gains and losses in human malignant pleural mesothelioma cell lines: Involved loci and genes Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach Year: 2010
Mutations in the retinoblastoma-related gene RB2/p130 in lung tumours and suppression of tumour growth in vivo by retrovirus-mediated gene transfer Source: Annual Congress 2002 - Thoracic oncology: biology Year: 2002
BMPR2 gene delivery shifts intracellular Smad activation profile Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology Year: 2012
Late Breaking Abstract: Real-time PCR versus direct sequencing in detection of EGFR T790M and L858R mutations – The sensitivity comparison Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach Year: 2010
LSC - 2021 - Mapping of Kras mutations during chemical carcinogenesis Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
The diagnosis and incidence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation in lung adenocarcinoma Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015
High expression apoptotic proteins; P53, FAS, and BAX associated with down regulation of BCL-2 in tuberculosis granulomas: an immunohistochemistry study Source: Eur Respir J 2005; 26: Suppl. 49, 454s Year: 2005